This is research, not a buy or sell recommendation. Robo-advice in Taiwan requires an FSC licence; FEAF analyses, explains and monitors, and the investor makes the decision. Judgement thresholds are working rules pending review by the team's finance members.
Plain-language summary of valuation, growth, profitability, balance sheet, and recent MOPS filings.
Mixed picture: 2 strengths against 3 watch-outs. Weigh them against your own goals.
Points to watch for a moderate profile: see the items marked above.
In plain words
Stock 4164 registered revenue growth of 22.2% in 2025 and 5.6% year on year in Q3 2026, along with a positive free cash flow of 134 NT$ million in 2025. However, the company presents weak profitability with a return on equity of 2.9% and a 4.7% net margin, alongside a heavy debt load with liabilities reaching 53.3% of total assets in Q3 2026. Furthermore, its P/E of 22.37 is well above the Biotechnology and medical median of 15.31 across 38 listed peers, making it priced richer than peers. Ultimately, all investment decisions remain entirely in the hands of the investor.
Written by gemini-3.6-flash from the facts above; every number was checked against them.
Strengths
+Revenue grew 22.2% in 2025; latest quarter Q3 2026: 5.6% year on year. source (Financials) →